IV DNase for ICU sepsis with organ stress
Part of Infections clinical trials.
This Phase 1 study tests whether an IV medicine called DNase I can safely help people with sepsis who are having worsening organ function. It’s designed to see if the treatment is tolerated and could improve outcomes for ICU patients with early sepsis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older
- You were admitted to the ICU within the last 48 hours
- Your doctor believes you have an infection causing your illness
- You have new/worsening organ stress from sepsis (SOFA score at least 2 higher than your baseline)
- You’re expected to stay in the ICU for at least 72 hours
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (NAI) added to standard care for sepsis in the ICU to see if it helps improve immune function and recovery. It is for people with very low lymphocyte counts who meet specific timing and health requirements.
This trial tests a medical device (NucleoCapture) that may remove substances called circulating DNA and NETs from the blood in people with sepsis and breathing failure. The goal is to check safety and see whether it can improve blood markers and possibly outcomes.
This trial looks at natural molecules that help the body resolve severe infections. Researchers want to understand how these molecules affect recovery and identify patient types that respond best. It may help improve treatment for people in the ICU with serious infections.
This trial tests if a special fluid given through a vein can protect and repair the lining of your blood vessels during sepsis. Sepsis is a dangerous reaction to an infection that can damage organs. This study aims to see if this treatment helps patients in the intensive care unit (ICU) recover better.
This trial looks at how certain genetic elements may affect the immune system in older adults with sepsis. It aims to understand why older patients may respond differently to severe infections.
This study tests whether adding a sedative called dexmedetomidine, along with your current care, can improve blood flow in small blood vessels under the tongue for people with septic shock in the ICU.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.